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Diabetic nephropathy (DN) is one of the major complications of diabetes mellitus (DM), leads to chronic kidney disease (CKD),
and, ultimately, is themain cause for end-stage kidney disease (ESKD). Beyondurinary albumin, no reliable biomarkers are available
for accurate early diagnostics. Urinary extracellular vesicles (UEVs) have recently emerged as an interesting source of diagnostic
and prognostic disease biomarkers. Here we used a protease and respective protease inhibitor array to profile urines of type 1
diabetes patients at different stages of kidney involvement. Urine samples were divided into groups based on the level of albuminuria
and UEVs isolated by hydrostatic dialysis and screened for relative changes of 34 different proteases and 32 protease inhibitors,
respectively. Interestingly, myeloblastin and its natural inhibitor elafin showed an increase in the normo- and microalbuminuric
groups. Similarly, a characteristic pattern was observed in the array of protease inhibitors, with a marked increase of cystatin B,
natural inhibitor of cathepsins L,H, andB aswell as of neutrophil gelatinase-associated Lipocalin (NGAL) in the normoalbuminuric
group. This study shows for the first time the distinctive alterations in comprehensive protease profiles of UEVs in diabetic
nephropathy and uncovers intriguing mechanistic, prognostic, and diagnostic features of kidney damage in diabetes.
1. Introduction
Diabetes mellitus (DM) has emerged as one of the major
global health problems and a heavy burden for all healthcare
systems [1]. Current predictions estimate that by 2025 more
than 480 million people globally will have an altered glucose
tolerance and 380million will have developed type 2 diabetes
[2]. Among diabetic complications diabetic nephropathy
(DN) has already become the leading cause of end-stage kid-
ney disease (ESKD) worldwide [3, 4]. Moreover, progressive
decline of kidney function is associated with an increase in
all-cause mortality and severe cardiovascular complications
in patients with diabetes [5–7]. Despite important advances
in understanding, for example, the molecular pathways
associated with the pathogenesis of DN [8, 9], the clinical
management of patients, and pharmacological treatments to
protect the kidney function are not completely satisfactory
[10, 11].
The diagnosis of DN is based on clinical parameters
including the measurement of urinary albumin excretion
rate (AER), assessment of glomerular filtration rate (GFR)
[12], and registering end-organ complications (retinopathy or
neuropathy). Leakage of albumin into urine (albuminuria)
has been the goldenmarker to indirectly indicate the integrity
of the glomerular filtration barrier and as an index of kidney
functionality. Depending on severity of damage, the level of
albumin found in urine increases in a linear fashion. Patients
are commonly stratified as normoalbuminuric (<20𝜇g per
minute or <30mg/24 hours), microalbuminuric (20–200𝜇g
per minute or 30–300mg/24 hours), or macroalbuminuric
(>200𝜇g per minute or >300mg/24 hours) [13, 14]. In the
diabetic patient, the onset of microalbuminuria proceeding
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to macroalbuminuria typically appears between 5 to 15 years
and 15 to 25 years from the onset of diabetes [15, 16]. However,
in patients with type 1 diabetes the decline of GFR is not
always in concordance with the level of albuminuria andGFR
reduces without clear signs of albuminuria and conversely
reversion from microalbuminuria to normoalbuminuria can
happen [17]. These evidences suggest that more than 1
pathway may well be involved in the development of DN and
surrogate biomarkers in support of albuminuria are badly
necessary to predict the progression of DN.
In the last decade urinary extracellular vesicles (UEVs)
have gained considerable research interest due to their con-
tent of potential key molecules for intercellular communica-
tion and the possible use as source of biomarkers [18–20].
More in general cells secrete a surprising variety of vesi-
cles such as exosomes, microvesicles, exosome-like vesicles,
apoptotic blebs, and retrovirus-like particles (RLPs) into the
extracellular space [21, 22] apparently reflecting intracellular
processes. Thus, they provide a lucrative approach to bet-
ter define the molecular events associated with metabolic
disturbances as in diabetes. Moreover, UEVs have already
shown to provide a promising source of biomarkers and
their full potential has still to be utilised [23–25]. In this
study we reveal, for the first time, a comprehensive analysis
of proteases and proteases inhibitors in UEVs isolated from
healthy subjects and DN in type 1 diabetes.
2. Methods
2.1. Urine Samples. Control urine samples were collected
from twelve healthy volunteers among the laboratory staff,
aged 20–40, in accordance with ethical protocols of the
Dublin City University. First morning void urine was pro-
cessed within 3 h without addition of protease inhibitors.
Urine was anonymously tested by Combur 10 Test D dip-
stick (Roche Diagnostics, Basel, Switzerland) for the follow-
ing: specific gravity, leucocytes, nitrites, proteins, glucose,
ketones, urobilinogen, bilirubin, blood, and haemoglobin.
All patients participated in the Finnish Diabetic Neph-
ropathy (FinnDiane) study, a nationwide multicenter study
with the aim of identifying genetic and clinical risk factors for
diabetic nephropathy in type 1 diabetes. The study protocol
is in accordance with the Declaration of Helsinki, and it
has been approved by the local ethics committee in each
participating study centre. Urinary albumin excretion rate
(AER) was determined in 24 h urine collections by immuno-
turbidimetry (Pharmacia, Uppsala, Sweden).The renal status
was defined based on AER in at least two of three collections.
Patients were divided by AER categorically.
2.2. Vesicle Purification. UEVs were purified by a hydrostatic
filtration dialysis (HFD) system recently developed in our
group [26]. Briefly, control and DN urine samples were
centrifuged at a relative centrifugal force (RCF) of 2,000 g
calculated at maximum radius of 160mm in a swing bucket
rotor Benchtop Universal 320 centrifuge (Hettich Zentrifu-
gen, Tuttlingen, Germany) for 30min at room temperature
(RT) (without using break).
The supernatant (SN) was poured in a funnel con-
nected to dialysis membrane with a molecular weight cut-
off (MWCO) of 1,000 kDa as shown in supplemental Fig-
ure 1(S) (see Supplementary Material available online at
http://dx.doi.org/10.1155/2015/289734). The hydrostatic pres-
sure of the analyte solution is strong enough to push the
solvent through the mesh of dialysis membrane carrying
all the analytes below the MWCO (HFDb). Thus, after the
first step of concentration (∼3mL) the funnel is refilled
with 200mL of deionised filtrate (0.22 𝜇m) water to rinse
what is left in the concentrated urine until the volume of
∼5mLwas reached again.This concentration process is called
“hydrostatic filtration dialysis.” The retained solution above
the 1,000 kDa cutoff (HFDa) was used for all the following
experiments.
2.3. Protein Assay, Gel Electrophoresis, and Western Blot.
Protein quantification was determined by Coomassie [27]
microassay. Proteins were separated by SDS-PAGE employ-
ing freshly cast T 6–18%, C 2.6% gradient resolving gel
(80mm × 50mm × 1.5mm) [28]. Protein amounts (based on
the Bradford assay) were first dried by vacuum concentration
and then resuspended in a strong chaotropic solution made
of the following: 7M urea, 2M thiourea, 5% (w/v) SDS,
40mMTris-HCl, pH 6.8, 0.5mMethylenediaminetetraacetic
acid (EDTA), 20% (v/v) glycerol, and 50mM dithiothreitol
(DTT) in a ratio of 0.25 𝜇g of protein per 𝜇L of solution
[29]. Protein denaturation was obtained after an overnight
(ON) incubation at RT. After electrophoresis the gels were
either stained with colloidal Coomassie [30] or transferred
to 0.45 𝜇m nitrocellulose membrane (Whatman, Springfield,
UK) [31]. For Western blotting, membranes were saturated
with Odyssey blocking buffer (LI-COR Biosciences, Lin-
coln, MA) and incubated with specific antibody as fol-
lows: rabbit anti-tumour suppressor gene (TSG101) (Sigma
Aldrich, Dorset, UK), rabbit anti-ubiquitin (Dako, Glostrup,
Denmark), and mouse anti-proteinase 3 (R&D Biosystem,
Minneapolis, MN). After 6 washes in PBS-Tween (0.1%, v/v)
membranes were incubated with infrared dye-coupled sec-
ondary antibody with a fluorescent tag (an emission of either
680 nm or 700 nm) (LI-COR Biosciences) dilution 1 : 5000
2 h incubation RT. Determination of molecular weight of
all bands of interest and quantification of the signal were
performed by Odyssey Infrared Laser Scanner software (LI-
COR Biosciences).
2.4. Proteases and Protease Inhibitor Profiles. Proteome pro-
filer human protease array kit and proteome profiler human
protease inhibitor array kit (R&D Systems) were used to
detect 34 proteases and 32 inhibitors, respectively. HFDa
pooled fractionswere dried by vacuum concentration (miVac
speed trap, GeneVac Ltd, Ipswich, UK) and resuspended in
50 𝜇L of 0.3% (w/v) sodium dodecyl sulphate (SDS) for 2
hours. Samples were diluted to 1mL with Array buffer 6 plus
0.5mL of Array buffer 4 (both buffers from R&D Systems).
Fifteen microliters of reconstituted detection antibody cock-
tail was added to the sample solution and incubated for 1 hour
at RT in end-over-end agitation. Mix sample-antibody solu-
tions were incubated overnight at 6∘C with the membrane
on a rocking platform shaker. After three 10-minute washes
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with 1x buffer, the membranes were incubated with infrared
dye-coupled streptavidin with a fluorescent tag emitting at
800 nm (LI-COR Biosciences), 1 : 2000 dilution for 1 h at
room temperature on the rocking platform shaker. After
three × 10min wash with 1x Wash Buffer the membrane
slides were acquired by Odyssey Infrared Laser Scanner (LI-
COR Biosciences) and relative quantification analysis was
performed by Odyssey Infrared Laser Scanner software (LI-
COR Biosciences).
2.5. Gelatin Zymography. Gelatin zymography was per-
formed using gradient sodium dodecyl sulfate gel elec-
trophoresis (SDS-PAGE, T = 6–18%C= 2.6%) copolymerized
with 2mg/mL pig skin gelatin type B (Sigma). UEVs (5 𝜇g per
group) were incubated overnight in nonreducing Laemmli
buffer [28]. After electrophoresis, gels were washed twice
for 30 minutes in 2.5% (v/v) Triton X-100 at 4∘C and were
incubated overnight in collagenase buffer (50mM Tris–HCl,
pH 7.8 with 5mM CaCl
2
at 37∘C). Gels were stained with
Coomassie BlueR 250 (Bio-Rad) in 40% (v/v) methanol and
10% (v/v) acetic acid for 1 hour andwere destained in the same
solution without dye. Gelatinase activities were visualized as
distinct bands, indicating proteolysis of the substrate [32].
2.6. Spectrophotometric Assay for Protease Activities. The
proteolytic activities of specific group of proteases in normo-,
micro- and macroalbuminuric HFDa fractions were assayed
using 0.1mM glycyl-prolyl-p-nitroanilide (GP-pNA) and
0.25mM N-benzoyl-proline-phenylalanine-arginine-p-ni-
troanilide (Be-PFR-pNA), N-methoxysuccinyl-alanine-ala-
nine-proline-valine-p-nitroanilide (Me-AAPV-pNA), and
succinyl-alanine-alanine-proline-phenylalanine p-nitroanil-
ide (Suc-AAPFpNA) chromogenic substrate of chromogenic
substrates to establish activity of DPP IV, Kallikreins,
proteinase 3, and cathepsins, respectively [23, 33–35]. Assays
were performed for 20min under same conditions of
100mM Tris-HCl buffer pH 7.8 with addition of 5mMCaCl
2
except for GP-pNA, for which 100mM Tris-HCl buffer
pH 8.6 was used. Incubations were performed at 37∘C for
20min in 96-well flat bottom microplates (Greiner Bio One
Kremsmu¨ster, Austria). Reactions were stopped by 30% (v/v)
final concentration of acetic acid. Results were read using
410 nm wavelength in Biotek PowerWave XS device (BioTek
Instruments Inc., Winooski, VT). The specific activity has
been defined as 𝜇mole of 4-nitroaniline released per minute
by one milligram of the protease under the assay conditions.
Assays were performed for intact vesicles (without treatment)
and after delipidation [36]. Briefly, an equivalent of 100 𝜇g
of proteins from each sample was resuspended in milliQ
water in total volume of 375𝜇L. Next, 675𝜇L of delipidation
solution made of 60% (v/v) diisopropyl ether (DIPE) and
40% (v/v) butanol were added. Samples were vortexed and
centrifuged for 10min at 5000 rpm at RT. Upper phase was
removed; 1125 𝜇L of DIPE was added to aqueous phase
and mixed end-over-end for 5min at RT. Samples were
then centrifuged at 5000 rpm for 5min in RT and the
upper phase was discarded while tubes were placed under a
fume hood to remove traces of an organic phase. Bradford
assay was performed to establish protein concentration and
samples were diluted to obtain an optimal concentration for
colorimetric assay.
3. Results
In the pilot study 12 (6 males and 6 females) control volun-
teers provided 15mLofmidstreamfirstmorning urine.Thirty
seven urine samples from diabetes patients, with different
levels of albumin-proteinuria were studied. After enriching
UEVs by hydrostatic filtration dialysis, samples were assayed
in electrophoresis and Western blots for general protein
patterns and detection of the respective vesicle markers
including tumor suppressor gene 101 (TSG101) specific for
exosome vesicles (Figure 1).
3.1. UEVsCharacterization. Silver stained gels showed a good
overlapping pattern with amoderate interindividual variabil-
ity, most likely due to variable amounts of Tamm-Horsfall
Protein (THP). Interestingly, TSG101 assay also showed a
progressive signal decrease in themicro- andmacroalbumin-
uric groups, respectively. This trend was even more evident
when urine pools were created for the protease and protease
inhibitor arrays (Figure 2). Moreover, a detectable shift of the
apparentTSG101molecularweight (MW)was observedwhen
pools were run in adjacent lanes in the same gel. This most
likely reflects changes in posttranslational modifications of
exosome components during disease course. These results
were confirmed in two independent Western blots, the
second of which was carried out with an optimised gradient
gel to have a better separation in theTSG101molecular weight
(MW) region. In order to investigate this alteration in detail
we assayed the ubiquitination state of exosomes. Although
the precise molecular mechanism of the vesicle formation
and protein recruitment needs to be fully elucidated, it seems
apparent that this posttranslation modification (PTM) faith-
fully reflects the disease pathogenesis. Interestingly, ubiquiti-
nation is involved in a variety of cellular processes, including
protein sorting and translocation inside the vesicle lumen
during vesicle biogenesis as well as in protein degradation
[37]. In support of this, Western blotting revealed a specific
ubiquitination pattern in the DN groups. Anti-ubiquitin
antibody used in this screening recognised free ubiquitin and
monoubiquitinated protein. In all theDNgroups it is possible
to observe a strong signal at 8.5 kDa corresponding to the
monomeric ubiquitin and 17 kDa (white rectangle) which is
absent in the healthy control. Moreover a specific pattern
in the normo-, micro-, and macroalbuminuric groups with
an apparently relative changing for some bands (asterisk) is
visible between 50 and 75 kDa.
3.2. Proteases Array and Relative Quantification. Despite the
fact that the challenges of using sample pools have been
thoroughly debated, pools for each study group were created
to overcome substantial limitation such as a relative protein
recovery from a limited volume of urine. Moreover a super-
pool made of the same amount of protein for each HFDa
sample was created to normalise the relative quantitative
changing of the proteases array (Figure 3(a)) and overcome
the lack of a housekeeping protein.
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Figure 1: SDS-PAGE protein pattern and TSG101 detection: Immunodetection of the exosome marker protein TSG101 from the same order
in the silver staining gels. Four 𝜇g of protein (Bradford assay) was loaded per sample in each lane. Molecular weights are expressed in kilo
Dalton.
Membrane slides were analyzed at the same time adjust-
ing the intensity of the laser to reach the limit of saturation for
the most abundant spot. The spots in positions A1,2, A19,20,
and E1,2 represent the positive controls. The absence of spots
in position E 7,8 (white rectangular), which is the negative
control, indicates the specificity of the antibody cocktail.
Table 1 reports changes of ±1.5-fold of the proteases, with
respect to the healthy control. The complete list is available
in a spreadsheet as supplemental Table 1. A positive signal of
29 proteases was detected out of 34, out of which 16 showed
a significant change during progression of DN. Figure 3(b)
shows the plots as bar chart of the fluorescent intensity (F.I.)
for each protease normalised by the F.I. of the superpool.
Positive spots were considered as those with a detection limit
(signal-to-noise ratio) ≥3.
A set of proteases appear to progressively increase in
different groups of DN patients (especially for the cathepsin
family with a progressive increase of A, C, D, L, and Z) while
only cathepsin E seems to decrease following a trend which
becomes significant (less than 1.5-fold) in themacroalbumin-
uric group.
In the family of Kallikreins, Kallikrein 3/PSA, Kallikrein
10, Kallikrein 13, and Kallikrein 6 could be biased by the
gender distribution of samples in the groups.Metalloprotease
MMP9 is abundantly present in the normoalbuminuric group
while MMP2 showed a progressive decrease reaching the
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Figure 2: SDS-PAGE protein pattern, TSG101, and ubiquitin detection of pooled samples. Two 𝜇g of protein (Bradford assay) was loaded per
sample in each lane. Molecular weights are expressed in kilo Dalton. H: healthy control, N: normoalbuminuric, Mi: microalbuminuric, and
Ma: macroalbuminuric.
threshold of −1.5-fold in the micro- and macroalbuminuric
groups. Other proteases which showed an interesting trend
are DDP IV targets of gliptins and proteinase 3 (PRTN3)
or myeloblastin. DDP IV decreased in the normoalbuminic
group and then increased during progression of DN while
proteinase 3 (PRTN3) has an opposite trend with a marked
increase in the normoalbuminuric and microalbuminuric
group to reach a normal level in themacroalbuminuric group.
3.3. Protease Activities. Beside the relative quantitative
amount we checked the activity of some of these proteases by
gelatine zymography for metalloproteases (Figure 4) which
confirmed a clear increase of gelatinase activity in the
normoalbuminuric group and by chromogenic substrates for
DPP IV, Kallikreins, cathepsins, and PRTN3 (Figure 5). Spec-
trophotometric assays were performed in native condition
and after organic delipidation to release proteases which can
be localized in the vesicle lumen. After delipidation only
the Kallikrein family was significantly affected (full loss of
activity) while all the other protease activities maintained the
same profile. Although there is a substantial increase of the
cathepsin expression in the protease array, the colorimetric
assay showed a decrease of the activity in the DN groups.
Moreover, it is interesting to notice that the activity of DPP
IV was much lower in the DN groups independently of the
levels detected in the array. Proteinase 3 activity was high
in the normoalbuminuric group but in the other groups it
remained unchanged despite the higher levels especially in
the microalbuminuric group. Since proteomic profiling of
UEVs reported the presence of several protease inhibitors
[18, 19], such discrepancy between activity and expression
levels could be caused by the presence of protease inhibitors.
3.4. Protease Inhibitor Array and Relative Quantification.
Based on the same assay, a protease inhibitor array to screen
the expression of protease inhibitors was performed. Out
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Figure 3: Protease array. (a)Nitrocellulosemembrane slides were acquired at the same time as fluorescent intensity. (b) Relative quantification
of positive protease (signal-to-noise ratio ≥3) was normalised by a pool made of all the samples included in the analysis. P: pool, H: healthy
control, N: normoalbuminuric, Mi: microalbuminuric, and Ma: macroalbuminuric.
Table 1: Proteases array coordinate, features, and changing fold.
Coordinates Protein name Uniprot number Gene name Vesiclepedia Isoform specificity Normo Micro Macro
A5, A6 ADAM9 Q13443 ADAM9 √ Ectodomain −2.16 −2.62 −2.92
A11, A12 Cathepsin A P10619 CTSA √ Proform and active 1.46 5.93 4.34
A15, A16 Cathepsin C P53634 CTSC √ Proform and active 2.47 2.98 2.50
A17, A18 Cathepsin D P07339 CTSD √ Proform and active 4.00 6.62 6.88
B3, B4 Cathepsin E P14091 CTSE √∗ Proform and active −1.11 −1.29 −1.63
B5, B6 Cathepsin L P07711 CTSL1 √ Proform and active −1.01 2.95 2.27
B11, B12 Cathepsin X/Z/P Q9UBR2 CTSZ √ Proform and active 2.63 8.13 7.19
B13, B14 DPPIV/CD26 P27487 DPP4 √ Ectodomain −1.84 −1.41 1.00
B15, B16 Kallikrein 3/PSA P07288 KLK3 √ Proform and active −2.13 1.91 1.68
C3, C4 Kallikrein 6 Q92876 KLK6 √ Proform and active 1.63 1.34 −1.35
C7, C8 Kallikrein 10 O43240 KLK10 √‡ Proform and active 1.87 1.93 1.90
C11, C12 Kallikrein 13 Q9UKR3 KLK13 X Proform and active 4.70 4.38 2.44
C15, C16 MMP-2 P08253 MMP2 √ Proform and active −1.36 −1.50 −1.52
D7, D8 MMP-9 P14780 MMP9 √ Proform and active 6.40 1.83 −1.02
D13, D14 Neprilysin/CD10 P08473 MME √ Ectodomain −1.89 −1.30 −1.37
E3, E4 Proteinase 3 P24158 PRTN3 √ Active 4.15 5.20 1.96
∗Reported in vesiclepedia database in mouse and rat species.
‡Reported in vesiclepedia database as mRNA.
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Figure 4: Protease chromogenic activity. Protease activities were assessed by specific chromogenic substrates for DDPIV Gly-Pro-p-
nitroanilide (GP-pNA), leukocyte proteinase 3, and elastase (N-methoxysuccinyl Ala-Ala-Pro-Val-p-nitroanilide M-MeAAPV-pNA). Two
𝜇g of protein (Bradford assay) was used per replica. The bar represents the standard deviation of the technical triplicate.
of 32 inhibitors 19 were present in the same pool, and 15
showed more than 1.5-fold change (Table 2 and Figure 6).
Also in this array we can identify different trends. Firstly, 6
inhibitors appeared to be more abundant (cystatin B, fetuin
B, angiotensinogen, serpin A8, serpin F1, and elafin) progres-
sively in the 3 diabetic groups.Those with decreased amounts
showed either a progressive decrease which becomes signif-
icant in the micro- and/or macroalbuminuric groups (e.g.,
serpin B5 and TIMP-2) or very low amount in all the 3
DN groups (cystatin C E/M, EMMPRIN/CD147, HA-2, and
HE4/WFDC2). Finally, two protease inhibitors (Lipocalin-
2/NGAL and Protease Nexin II) showed a peculiar increase
8 Journal of Diabetes Research
Table 2: Protease inhibitor array, coordinates, features, and changing fold.
Coordinates Protein name Uniprot number Gene name Vesiclepedia Normo Micro Macro
A3, A4 Protease Nexin II P05067 APP √ −1.75 −1.37 −1.90
A5, A6 Cystatin A P01040 CSTA √ −1.35 −1.62 −1.73
A7, A8 Cystatin B P04080 CSTB √ 3.74 2.39 2.91
A11, A12 Cystatin E/M Q15828 CST6 √ −2.75 −1.71 −2.36
A13, A14 EMMPRIN/CD147 P35613 BSG √ −2.05 −2.27 −3.08
A15, A16 Fetuin B Q9UGM5 FETUB X 1.11 1.44 1.68
B3, B4 HAI-2 O43291 SPINT2 √‡ −2.38 −2.43 −2.82
B5, B6 HE4/WFDC2 Q14508 WAP 5 √‡ −2.44 −1.81 −1.99
B9, B10 Lipocalin-1 P31025 LCN1 √ −1.62 −1.30 −1.47
B11, B12 Lipocalin-2/NGAL P80188 LCN2 √ 2.72 −1.30 −1.61
B17, B18 Serpin A8 P01019 AGT √ −1.19 1.79 1.50
C7, C8 Serpin B5 P36952 SERPINB5 √ −1.03 1.06 2.67
C9, C10 Serpin B6 P35237 SERPINB6 √ −1.43 −1.57 −1.81
C15, C16 Serpin F1 P36955 SERPINEF1 √ −1.23 1.69 2.36
D5, D6 TFPI P10646 TFPI √ −1.44 −1.46 −1.54
D7, D8 TFPI-2 P48307 TFPI2 X −1.31 −1.44 −1.61
D9, D10 TIMP-1 P01033 TIMP1 √ −1.31 −1.14 −1.57
D11, D12 TIMP-2 P16035 TIMP2 √ 1.29 −1.47 −1.86
D17, D18 Elafin P19957 PI3 X 4.62 2.84 1.15
‡Reported in vesiclepedia database as mRNA.
Try H N Mi Ma
Figure 5: Zymography SDS-PAGE of vesicle-associated gelatinases.
One 𝜇g of protein per each pool (Bradford assay) was loaded in each
lane. Gel was incubated at 37∘C for 16 hours. Try: Trypsin (50 ng),
H: healthy, N: normoalbuminuric, Mi: microalbuminuric, and Ma:
macroalbuminuric pools.
in the normoalbuminuric group and a sharp decrease in the
macroalbuminuric cohort.
In order to establish whether there is any functional
interconnection between proteases and protease inhibitors
we used the Kidney & Urinary Pathway knowledge Base
(KUPKB) [38] designed to collect data set from scientific
publications and other datasets related specifically to renal
diseases. The query of the KUPKB algorithm provided the
protein network presented in Figure 7. Out of 30 entries
which are up- or downregulated by 1.5-fold in the protease
and protease inhibitor arrays, 11 entities were found to be
connected as a network together.Within the networkwe have
found that cathepsin L via cystatin A is connected to the
metalloproteases 9 and 2 whose dysregulation is potentially
involved in the progression of DN [39]. Interestingly, PRNT-
3 mRNA was reported to be upregulated in type 2 diabetic
nephropathy [40]. Thus, a further screening in Western blot
was carried out evaluating the full cohorts of samples as
shown in Figure 8 qualitatively confirming the array data.
4. Discussion
Diabetic nephropathy (DN) is a major complication of
diabetic patients, constituting the leading cause of ESKD and
considerably increasing cardiovascular risk and associated
mortality. Defining the pathophysiologic mechanisms in DN
is necessary to better understand the disease and identify new
targets for therapeutic intervention. Kidney lesions can start
to develop early during the quiescent period when the patient
is still normoalbuminuric and with normal glomerular filtra-
tion rate (GFR) [17].
Microalbuminuria has a solid role in the clinical practice
andmanagement of diabetic kidney disease (DKD).However,
an increasing number of studies have shown that decrease of
GFR can occur independently from the presence of albumin-
uria or progression to macroalbuminuria and therefore the
utility of albuminuria itself has been questioned [41].Thus, in
addition to albumin excretion rate (AER) and GFR, selected
biomarkers for the detection of early functional abnormalities
have been proposed and recently reviewed by Macisaac et al.
[42].
Recently urinary exosomes or, more in general, urinary
extracellular vesicles (UEVs) have been actively studied
for their biological role as a potentially new cell-to-cell
communication system. Despite the partly overlapping and
confusing nomenclature, EVs can be divided into various
main categories with respect to their secretory pathway [21,
22]. Thus, exosome vesicles are formed by inward invagina-
tion of the endosomal membrane in an ubiquitin-dependent
mechanism which requires the Endosomal Sorting Complex
Required for Transport (ESCRT) machinery. Exosomes are
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Figure 6: Protease inhibitors array. (a) Nitrocellulose membrane slides were acquired at the same time as fluorescent intensity. (b) Relative
quantification of positive protease (signal-to-noise ratio ≥3) normalised by a pool made of all the samples included in the analysis. P: pool,
H: healthy control, N: normoalbuminuric, M: microalbuminuric, and Ma: macroalbuminuric.
then released in the extracellular space when multivesicular
bodies (MVBs) of late endosomes fuse with the plasma
membrane and release their intraluminal vesicle cargo [43].
Microvesicles are shed vesicles or membrane particles which
derive directly from the outward budding of plasma mem-
brane in response to a variety of pathophysiological stimuli
[44, 45]. Furthermore, EVs can mediate intercellular com-
munication by delivering elements of genetic content from
one cell to another in a paracellular fashion [46].Thus, UEVs
faithfully reflect the antigenic characteristics of their parent
cells thus making them excellent cell-type specific. This has
led to an explosion of interest in EVs as potential source
of biomarkers as mirror of the pathophysiology of the cell
of origin [19, 47]. Thus, UEVs can provide a good platform
as a surrogate of a “fluid biopsy” to support the clinical
management of, for example, diabetic patients, assuming the
DNkidney damage is reflected in the repertoire of UEVswith
a specific fingerprint at each stage of disease progression.
The first aim of this study was to isolate and charac-
terize UEVs from healthy donors and 3 cohorts of DN
grouped according to the AER using a new isolation method
developed in our group [26]. This is based on a hybrid
ultrafiltration-dialysis systemwhich enriches vesicleswithout
the interference of soluble protein like human serum albumin
(HSA). As shown in Figure 1 for all the samples under
investigation, themain protein present in theUEVs is Tamm-
Horsfall Protein (THP). THP is abundant in the healthy
controls and it progressively decreases in the DN groups.
No evidence of massive presence of human serum albumin
(HSA) even in the macroalbuminuric group was seen. As
expected, more prominent bands in the microalbuminuric
and macroalbuminuric groups are visible at 62, 52, and
25 kDa and these correspond to the heavy and light chains
of immunoglobulin (Ig) isotypes 𝛼, 𝛾, 𝜅, and/or 𝜆 chains.
Immunoglobulins have been identified in the proteome
profiling of UEVs [18, 19] and elevated concentration of IgG
and IgA in urine has been proposed as a novel mecha-
nism of kidney damage independent from charge and size
impairment in early DN [48, 49]. More dedicated studies are
necessary to investigate the role of vesicles-Ig interaction in
DN for their role.
Detection of the exosomal marker TSG101 confirmed the
abundance of UEVs in the HFDa fractions. Interestingly,
we noticed a progressive decrease of the signal during
worsening of AER. Additionally, a shift of the molecular
weight of TSG101 was observed (Figure 2). TSG101 can be
acetylated [50] and/or ubiquitylated [51] and as component
of the ESCRT-I machinery it binds ubiquitylated protein to
sort it out into vesicles during its biogenesis to form the
multivesicular body (MVB) which then either can release
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Figure 7: Urinary and kidney network map. A biological network
of interaction using 30 proteases and proteases inhibitor entries
extrapolated from the respective arrays was analysed by KUPKB
[38]. Selected proteins were 1.5-fold up- or downregulated with
respect to the healthy control. According to their intracellular
pathways, several proteases can bind and degrade also endogenous
inhibitors. This type of binding and interactions can add further
complexity to the respective networks, and proteolytic signals them-
selves may end up in multiple directions. Accordingly, cathepsin
L inactivates serpinA1 [75] and MMPs can inactivate a variety
of serpins [76]. Conversely, some cystatins interact with MMP-9,
still preserving the catalytic function after autodegradation [77].
Interestingly, angiotensinogen (AGT) decreases, through the action
of AGT II, the transcription of MMP-1, MMP-2, TIMP-1, TIMP-2,
and TIMP-3 but increases MMP-9 in human cardiomyocytes [78].
its vesicle cargo (exosomes) outside the cell and/or fuse
with lysosome for degradation [52]. Thus, the ubiquitinated
pattern of UEVs in the healthy and DN groups was checked
by Western blot utilising a polyclonal antibody which recog-
nised ubiquitin and monoubiquitinated proteins (Figure 3).
Interestingly, the DN samples, at different stages of disease,
provided a well defined and characteristic ubiquitome. This
result along with decrease of TSG101 signal suggests that an
impairment of the endosome/vesicle trafficking happens in
the early stages of disease. Ubiquitin, more in general the
ubiquitin-proteasome, plays a pivotal role in the degradation
of misfolded proteins, concentration, and turnover of cellular
proteins. Thus the ubiquitin-proteasome system works in
synergy with lysosomal proteases, caspases, calpains, and
separases to generate shorter polypeptides accessible to the
proteasomes system for a full protein degradation [53]. Our
results show convincingly that there are major intracellular
changes reacting to altered microenvironment and this is
reflected in the void UEVs.
Proteases cover an important role not only in the patho-
genesis of DN [39] but more in general as the dynamic reac-
tion obviously needed to keep the intracellular homeostasis,
in our case to fight back the hyperglycaemia induced changes
[54, 55]. In this study we wanted to focus our attention on
proteases first and their well established inhibitors and how
they are represented in the UEVs as indicators of intracellular
events.
Sixteen and nineteen proteases and inhibitors, respec-
tively, changed by ±1.5-fold with respect to the healthy group.
Cathepsins of the A, C, D, L, and XZP classes were found
as markedly more abundant in the DN groups. The only one
less represented is cathepsin E, while cathepsins B, S, and V
did not show any change. Cathepsins are lysosomal proteases,
which can exert their proteolytic activity in the extracellular
space in extracellular matrix (ECM) remodeling, and in
synergy with MMP are implicated in the development of
renal diseases (CRDs) [56, 57]. Beside the increased level
of cathepsin L the protease inhibitors array showed a con-
comitant increase of cystatin B a thiol proteinase inhibitor
which, reversibly, binds cathepsin L [58]. Interestingly, neu-
trophil gelatinase-associated Lipocalin (NGAL) binds and
preserves metalloproteinase 9 (MMP-9) from degradation
thus supporting its gelatinase activity [59]. Increase of urinary
excretion of NGAL-MMP-9 has been described in diabetic
subjects in a gender-specific manner [60]. In our study
proteases, protease inhibitors arrays, and their functional
verification with zymography showed that this association is
also reflected inside the UEV fraction. Intriguingly, whether
these findings show a “spillover” reflection of the cellular
reaction to elevated glucose content or a mechanism to allow
specific targeting to more downstream sites of protease needs
should be studied in detail.
Increase of the urinary level of DPP IV associated with
microvesicles is correlated with the worsening of DN [23].
In our array, we found that the level of DPP IV decreases in
the normoalbuminuric group and then starts to progressively
increase in the samples from patients with micro- and
macroalbuminuria. Independently of the levels DPP IV, its
functional activity is markedly lower in the 3 DN groups than
in control.
Sun and colleagues [23] reported an increased excretion
of DPP IV associated with microvesicles in type 2 diabetic
patients. Their results are in contrast with the result of our
screening but the methodological approach can explain such
a difference. While in our study we collected the whole
amount of UEVs retained in the dialysis tube, they enriched
DPP IV using a specific monoclonal antibody anti-AD-
1 (leucine aminopeptidase). The authors reported it to be
expressed on the brush border of the proximal tubular in the
cortex (S1, S2 segments) and in the outer medulla and in the
medullary rays (S3 segments). However, DPP IV is widely
expressed also in the glomeruli [61] and an increase ofDPP IV
activity in podocytes is correlated with kidney injury [62, 63].
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Figure 8: Myeloblastin (PRNT3) immunodetection. Two 𝜇g of protein (Bradford assay) was loaded per sample in each lane. Nitrocellulose
membranes were acquired at the same time as fluorescent intensity. (a) Healthy Control. (b) Normoalbuminuric. (c) Microalbuminuric. (d)
Macroalbuminuric. (e) Average of the fluorescent intensity of each group. Molecular weights are expressed in kilo Dalton. H: healthy control,
N: normoalbuminuric, Mi: microalbuminuric, and Ma: macroalbuminuric.
Of course additional studies are necessary to better evaluate
changes in the DPP IV levels in microvesicles.
In order to analyze the link between the proteases and
their inhibitor we used the Kidney & Urinary Pathway
knowledge Base (KUPKB) [38] to specifically focus on
proteins/genes relative to pathways in the kidneys. Notably, a
distinct protein network as shown in Figure 7 was observed.
In addition to theMMPs and their relative inhibitors, two rel-
atively new proteins emerged which are potentially involved
in the complexity of DN pathogenesis: myeloblastin and
its natural inhibitor Trappin-2. Myeloblastin or proteinase
3 (PRTN3) is a serine protease present in granules and the
cell surface of neutrophils and monocytes. It can function
in a membrane bound or soluble form. It has pleiotropic
effects and multiple substrates including extracellular matrix
and cytokines [64, 65] and it can be found in urine [66].
Recruitment of neutrophils in glomeruli and the release of
PRTN3 potentially lead to endothelial dysfunction [67].More
recently podocytes have shown to actively regulate neutrophil
recruitment through action of glomerular endothelial cells
[68]. PRTN3 binds to the endothelial surface but it can
be also internalised inducing apoptosis [69, 70]. Moreover,
PRTN3 has been proposed as an inflammatory enzyme able
to digest insulin-like growth factor 1 (IGF-1) and the insulin-
like growth factor-binding protein-3 (IGFBP3) and promote
glomerular inflammation in type 2 diabetes. Interestingly,
endothelial dysfunction and inflammation have been recently
proposed as predictors of DN in type 1 and 2 diabetes
[71, 72]. Our results showed that also these mechanisms
can be monitored by detecting a combination of selected
proteases and their inhibitors. The protease array (Figure 3),
verified with the functional chromogenic activity (Figure 5)
and screening patients (Figure 8), confirmed an increase of
the level and activity already in the normoalbuminuric group:
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in patients with changes induced by hyperglycemia but with
no signs of permanent kidney damage yet. Indirectly we can
generalize that hyperglycemia leads also to inflammation,
contributes to the complexity of changes, and can be the
ultimate functional component for apoptosis and autophagy
[73]. This is supported by the dysregulated ubiquitination
mirrored in the UEVs (Figure 2). This is interesting as
very recently it has been reported that the ubiquitination-
dependent of coactivator-associated arginine methyltrans-
ferase 1 (CARM1) can mediate podocyte apoptosis in DN
[74]. Amore comprehensive analysis of the distinct proteases
and their association to their preferential pathophysiological
processes is warranted.
In conclusion, UEVs have a strong potential as key
elements for a fluid kidney biopsy by reflecting the respective
pathophysiology, exact mechanisms involved, and often also
information on the exact domain of the nephron affected.
Consequently, they also carry a great potential to develop
distinct inhibitors/activators. However, more detailed studies
and, most preferably, correlating findings with those from
tissue biopsies and clinical parameters are imperative. Here
we show that the new hydrostatic filtration dialysis method
offers an unbiased approach for vesicle enrichment from
urine and their subsequent use for distinct purposes of
protease inhibitor studies.
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